408.41
-12.34
(-2.93%)
Jun 19 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 404.25 - 419.50 |
| 52 week | 352.50 - 645.25 |
| Open | 419.50 |
| Vol / Avg. | 525,876.00/176,902.00 |
| Mkt cap | 811.08M* |
| P/E | 28.99 |
| Div/yield | 1.94/1.54* |
| EPS | 0.14* |
| Shares | 198.60M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 26.44% | 25.97% |
| Operating margin | 34.75% | 34.99% |
| EBITD margin | - | 41.24% |
| Return on average assets | 16.89% | 19.37% |
| Return on average equity | 19.96% | 22.87% |
| Employees | 680 | - |
| Carbon Disclosure Rating | - | - |
Address
330 Cambridge Science Park, MILTON ROAD
CAMBRIDGE, ENG CB4 0FL
United Kingdom - Map
+44-1223-696000 (Phone)
+44-1223-771600 (Fax)
CAMBRIDGE, ENG CB4 0FL
United Kingdom - Map
+44-1223-696000 (Phone)
+44-1223-771600 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Abcam Plc produces and distributes research-grade antibodies and associated products. Headquartered in Cambridge, the United Kingdom, the company distributes its products thru an online catalog.
Officers and directors
| Jonathan Milner Ph.D. | Chief Executive Officer, Executive Director | |
| Jeffrey Michel Iliffe | Chief Financial Officer, Company Secretary, Executive Director | |
| Jim Warwick | Chief Operating Officer, Executive Director | |
| Ed Ralph Ph.D | Chief Information Officer | |
| Mark Bushfield Ph.D | Scientific Director | |
| Jane Cooke | Director Corporate Services | |
| Philippe Cotrel | Commercial Director | |
| Michael Redmond | Non-Executive Independent Chairman of the Board | |
| Murray Edwin Hennessy | Non-Executive Director | |
| Anthony Francis Martin Ph.D. | Non-Executive Director |